The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial.

ABSTRACT:

Background and objectives

Mineralocorticoid receptor antagonism reduces morbidity and mortality in patients with heart failure, but the safety of these drugs in patients receiving dialysis is unclear. This study evaluated whether hyperkalemia and/or hypotension limited the use of eplerenone, a selective mineralocorticoid receptor antagonist, in hemodialysis patients.

Design, setting, participants, & measurements

This was a randomized controlled trial of prevalent patients receiving hemodialysis at five Canadian centers. Participants were randomly allocated to 13 weeks of eplerenone titrated to 50 mg daily (n=77) or a matching placebo (n=77). The primary outcome was permanent discontinuation of the drug because of hyperkalemia or hypotension. Secondary outcomes included hyper

SUBMITTER: Walsh M 

PROVIDER: S-EPMC4559523 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature